Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In order to learn more about follicular lymphoma and anti-cancer vaccines, we are collecting samples from people with this diagnosis. We then hope to make a vaccine from this tissue to help the immune system destroy cancer cells. We plan on keeping samples in the tissue bank indefinitely.
| Condition | Intervention |
|---|---|
|
Non-Hodgkin's Lymphoma |
Procedure: Procurement of Follicular B Cell Lymphoma Cells |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Procurement of Follicular B Cell Lymphoma Cells From Blood, Tissue or Malignant Effusion for the Purpose of Possible Use in Future Clinical Trials: A Minimal Risk Protocol |
Whole Blood Lymph node biopsy Drainage of an effusion Bone marrow biopsy
| Estimated Enrollment: | 40 |
| Study Start Date: | June 2007 |
| Estimated Study Completion Date: | June 2013 |
| Primary Completion Date: | August 2012 (Final data collection date for primary outcome measure) |
-
Procedure: Procurement of Follicular B Cell Lymphoma Cells
- The following tests and procedures will be performed: Approximately 50cc of peripheral blood will be drawn and stored in the tissue bank; patients who have follicular lymphoma cells circulating in the blood will have about 40cc's of blood drawn and stored for processing; patients undergoing a lymph node biopsy will have samples of the biopsy stored; patients having fluid drained from the abdomen or from around the lung will have some of their fluid saved to cell collection and processing; patients undergoing a bone marrow biopsy will have some of the sample stored for cell collection and processing.
Eligibility| Ages Eligible for Study: | 35 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Participants are selected because they have Non-Hodgkin's lymphoma.
Inclusion Criteria:
- Relapsed, refractory or de novo histologically confirmed follicular B-cell lymphoma with accessible lymph nodes, tumor mass or malignant effusion or peripheral blood
- 35 years of age or older
Exclusion Criteria:
- Uncontrolled active infection
- HIV or viral Hepatitis infection
- Other current malignancies except any in situ cancer or basal or squamous cell carcinoma of the skin
- Autoimmune cytopenias
Contacts and Locations| Contact: Eric Jacobsen, MD | 617-632-6633 | edjacobsen@partners.org |
| Contact: Caitlin Tesmer | 617-632-6840 |
| United States, Massachusetts | |
| Dana-Farber Cancer Institute | Recruiting |
| Boston, Massachusetts, United States, 02115 | |
| Principal Investigator: | Eric Jacobsen, MD | Dana-Farber Cancer Institute |
More Information
No publications provided
| Responsible Party: | Eric Jacobsen, MD, Principal Investigator, Dana-Farber Cancer Institute |
| ClinicalTrials.gov Identifier: | NCT00487513 History of Changes |
| Other Study ID Numbers: | 06-276 |
| Study First Received: | June 15, 2007 |
| Last Updated: | April 23, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Dana-Farber Cancer Institute:
|
Follicular B Cell lymphoma vaccination |
Additional relevant MeSH terms:
|
Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 16, 2013